Skip to main content
. 2022 Sep 23;8(38):eabo6638. doi: 10.1126/sciadv.abo6638

Fig. 4. CsA RGD-LNC effects on the progression and prevention of neovascularization.

Fig. 4.

(A) Scheme depicting the pathogenesis and intervention regime in the mouse model of OIR. (B) Representative images of retina whole mounts showing the retinal vasculature stained with fluorescein isothiocyanate (FITC)–dextran (green) at P17. Untreated control (without OIR and with OIR; control no OIR and control OIR) compared to free CsA and CsA RGD-LNCs–treated mice. Scale bars, 500 μm. (C) Quantification of the relative avascular area. (D) Quantification of the relative neovascular area. (E) Absolute CsA content in the posterior eye of mice with OIR at P17 after injection of CsA RGD-LNCs or free CsA at P12. n.q., not quantifiable. Results are presented as means ± SD of at least n = 5 (C), n = 8 (D), and n = 5 (E) mice per treatment group. Levels of statistical significance are indicated as *P ≤ 0.05 and ****P ≤ 0.0001. P values were determined by one-way ANOVA (C) and unpaired t test (D).